Immunocore (NASDAQ:IMCR) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Immunocore (NASDAQ:IMCR) from a hold rating to a buy rating in a report published on Monday.

Other research analysts have also issued reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, April 20th. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Immunocore presently has a consensus rating of “Hold” and a consensus target price of $56.71.

Immunocore Trading Down 2.6%

Immunocore stock opened at $34.05 on Monday. Immunocore has a 52 week low of $27.56 and a 52 week high of $40.71. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -61.91 and a beta of 0.73. The company has a 50 day moving average price of $30.22 and a 200 day moving average price of $31.26.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.51. The company had revenue of $106.68 million for the quarter, compared to the consensus estimate of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The company’s revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. Research analysts forecast that Immunocore will post 0.06 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Harbour Investments Inc. grew its position in Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after purchasing an additional 388 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Immunocore by 37.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after buying an additional 572 shares during the last quarter. R Squared Ltd lifted its stake in shares of Immunocore by 7.4% in the fourth quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after buying an additional 606 shares during the period. Leonteq Securities AG bought a new stake in shares of Immunocore in the fourth quarter valued at about $30,000. Finally, Orion Porfolio Solutions LLC grew its position in Immunocore by 4.5% during the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock worth $752,000 after buying an additional 1,031 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.